Author Archives: Lu Rahman

#Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models — inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain — are invaluable preclinical research tools that enable tumour studies in the context of a complete… Read More

#Cancer Research #News

#Antibodies #Covid-19 #Drug discovery

How to achieve accurate affinity profiling of a SARS-CoV-2 antibody in serum

Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in patients and vaccinated individuals. Fluidic Analytics’ application note explains why current technologies provide only an incomplete understanding of the… Read More

#Covid-19 #News

#Assay development optimisation & technology

Precision control of protein release to reconfigure bioprocessing

Dr J. Mark Treherne, Dr Christian Pernstich and Dr Michael Jones examine how the controlled release of proteins will  improve the reproducibility of cell-based drug discovery screens? Cell-based screening systems are now routinely incorporated as pivotal decision-making assays much earlier into the drug discovery process across most therapeutic areas and… Read More

#Editor's Choice #Exclusive Content #News

#Assay development & optimisation #Drug discovery #In vitro

Eurofins, a focus on drug discovery expertise

Eurofins Discovery is a CRO with a range of expertise in drug discovery. Christina Shasserre, Senior VP spoke to Lu Rahman about some of the company’s current COVID-related work as well as offering insight into the drug discovery landscape.   LR: Are you able to share some of Eurofins Discovery’s… Read More

#News #Opinion

#AI / data analytics / healthtech / informatics #Drug discovery

Precision medicine in the era of artificial intelligence

Dr Lotfi Chouchane and Dr. Javaid Sheikh, Weill Cornell Medicine-Qatar, outline the challenges and opportunities ahead for drug discovery Precision medicine is an emerging model for the next generation of clinical care that will capitalise on the dynamic interaction between individual biology, lifestyle, behaviour, and environment. It holds huge promise… Read More

#Exclusive Content #News #Trends & Analysis

#Toxicology

In vitro models for assessing drug toxicity: new approaches and development

Karissa Cottier, PhD Research Scientist, BioIVT, ADME-Tox, examines the ongoing development and advances to ensure drug efficacy and safety Researchers evaluate the efficacy and safety profiles of drug candidates, including their potential to cause liver damage, when considering whether to advance them in development programs. Drug-induced liver injury (DILI) is a… Read More

#Exclusive Content

#Covid-19 #Vaccines

Vaccine innovation in the age of COVID-19 & beyond

Traditional approaches for vaccine discovery and development are being reimagined and accelerated - leveraging technologies in novel ways to streamline workflows and forging collaborations. Dr. Sanjay Garg and Dr. Anis H Khimani, discuss key learnings and best practices during COVID-19 vaccine research and how we can take these forward to… Read More

#Covid-19 #Exclusive Content #News

#Immunology / Virology & Vaccines #Mass spectrometry / NMR

It’s all in the technique: how MS provides information on virus structure and function

Andreas Huhmer, Senior Director, Proteomics and Metabolomics, Thermo Fisher Scientific, examines the mass spectrometry techniques providing detailed insight into virus structure and function Our ability to quickly and accurately understand new viruses has been significantly tested in 2020, with the emergence of SARS-CoV-2, the coronavirus causing the COVID-19 pandemic. Since… Read More

#Exclusive Content

#Drug discovery #Flow Cytometry

Why flow cytometry in drug discovery is a real life-saver

Capable of boasting high-throughput, accurate, multiparameter and highly reproducible results, Urmi Roy, Global Product Manager Miltenyi Biotec outlines the benefits of flow cytometry offering case study examples for its use. Increasing numbers of drug discovery programmes are targeting cellular mechanism and phenotype as a promising avenue for new therapies. The… Read More

#Exclusive Content #News

#Immunology / Virology & Vaccines

Virus in a well – microplate-based assays for virology research

The COVID-19 pandemic has promoted global efforts to develop antiviral treatments and vaccines against SARS-CoV-2. The pandemic has put virology, a field of research that has been neglected for years, back on the map by Tobias Pusterla, BMG Labtech. In fact, the increase in occurrence and types of virus outbreaks… Read More

#Exclusive Content

#AI / data analytics / healthtech / informatics #Biotechnology

Intelligent thinking: the biotech business harnessing the power of AI

Sam Cooper founded Phenomic AI in 2017 alongside Oren Kraus, as an early stage biotech company seeking to commercialise AI approaches for pharmaceutical R&D. He discusses the role of AI in drug discovery with Lu Rahman. LR: Where are we with deep learning and drug discovery and how effective is… Read More

#Editor's Choice #Exclusive Content #News #Opinion

#Drug development #Drug discovery #Drug targets

Genetic modifiers: Why drug developers should care

Sebastian Nijman, Chief Scientific Officer, Scenic Biotech, explains why harnessing genetic modifiers holds great potential to address the present drug target vacuum and why every drug developer should care about them. According to the National Institute of Health (NIH), approximately 500 of the many thousands of human diseases have an approved… Read More

#Exclusive Content #News

#Assay development & optimisation #Drug discovery

Accelerating assay development optimisation for drug discovery

Dr. Zack Gurard-Levin, Chief Scientific Officer, SAMDI Tech offers five challenges and solutions for optimal assay development in drug discovery Developing a suitable assay is critical to identifying and characterising novel drug leads. While designing an assay may appear straightforward, developing the assay in an optimised format for a particular… Read More

#Exclusive Content

#Drug discovery

Metrion Biosciences and LifeArc extend drug discovery collaboration

Metrion Biosciences, a specialist ion channel CRO and drug discovery company, and LifeArc, an independent medical research charity, have announced a 12-month extension of their neuroscience drug discovery collaboration, as a result of the continued success of their ongoing agreement. The collaboration is focused on the discovery of novel selective… Read More

#Editor's Choice #News